Screener
Taysha Gene Therapies, Inc. TSHA Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344610
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net loss | $(46,639) | $(26,882) | $(89,049) | $(48,411) |
| Weighted-average shares of common stock outstanding used to compute net loss per common share, basic and diluted | 369,044,040 | 297,988,978 | 367,845,094 | 283,726,888 |
| Net loss per common share, basic and diluted | $(0.13) | $(0.09) | $(0.24) | $(0.17) |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s shares (diluted)?
- Taysha Gene Therapies, Inc. (TSHA) reported shares (diluted) of 369M in Q2 2026.
- How has Taysha Gene Therapies, Inc.'s shares (diluted) changed year-over-year?
- Taysha Gene Therapies, Inc.'s shares (diluted) increased by 23.8% year-over-year, from 298M to 369M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s shares (diluted)?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s shares (diluted) has grown at a 69.5% compound annual growth rate (CAGR), from 150.1M to 1.2B.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Taysha Gene Therapies, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude